Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05849103 · ClinicalTrials.gov registry record · NA

Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy

A NA study, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
NA
Development phase
343
Enrollment target

NCT05849103: Completed NA study, sponsored by Vanderbilt University Medical Center.

NCT05849103 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 343 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05849103, a NA study, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
NA
Development phase
343 participants
Enrollment target

Study Summary

Investigators propose a comprehensive management program for postpartum patients with HDP who are at risk for severe maternal morbidity and mortality. Our program will emphasize three key components: 1) self-monitoring of blood pressures with app-based reporting connected to our electronic health record, 2) blood pressure management directed by a program navigator with guideline and physician support and 3) facilitated transitions of care to primary care clinicians for hypertension management. Investigators will randomize 300 patents with HDP on postpartum day one with follow up through 3 months postpartum. Primary outcome will be blood pressure reporting at 7-10 postpartum. Secondary outcomes include blood pressure control at 7-10 days postpartum, identification and treatment of severe blood pressures, severe maternal morbidity, hospital readmission, triage visits for hypertension, postpartum and primary care visit attendance, and multiple patient-reported outcome measures. All outcomes will be stratified by race (Black and non-Black) to evaluate disparities and by tight versus usual blood pressure control to evaluate the impact of strict postpartum blood pressure control on outcomes. Investigators hypothesize that a comprehensive postpartum HDP management program will improve hypertension control for all patients and reduce disparities that affect Black patients, and that stricter blood pressure control will be associated with fewer adverse outcomes.

Primary Outcome

Proportion of participants with blood pressure values recorded in the office

Interventions

  • OTHER Blood Pressure Control Targets
  • OTHER Hypertension Management

Trial Details

FieldValue
Enrollment Target 343 participants
Start Date 2023-05-08
Est. Completion 2024-08-01
Phase NA

What the finished NCT05849103 record still lists

NCT05849103 is an interventional study that assigns participants to a tested intervention. The registered 343 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 2 interventions - of which Blood Pressure Control Targets is the first listed.

NCT05849103 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05849103 about?

NCT05849103 is a clinical study titled "Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy". Investigators propose a comprehensive management program for postpartum patients with HDP who are at risk for severe maternal morbidity and mortality. Our program will emphasize three key components: 1) self-monitoring of blood pressures with app-based reporting connected to our electronic health re...

What is the current status of trial NCT05849103?

This trial is currently completed. It is a NA study. The enrollment target is 343 participants. The study started on 2023-05-08. Estimated completion is 2024-08-01.

What interventions are being tested in trial NCT05849103?

The interventions under investigation include: Blood Pressure Control Targets (OTHER), Hypertension Management (OTHER).

Who is sponsoring clinical trial NCT05849103?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05849103's enrollment target sits among peer trials

343 302nd of 2000 higher than 1,699 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06733363 · 344 participants · Phase 2

    A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

  • NCT07179380 · 344 participants · Phase 3

    Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • NCT07304024 · 344 participants · Phase 1

    A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

  • NCT05283850 · 342 participants · Phase 2

    Surviving PEA in Roanoke (SPEAR) Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05849103, the US trial registry maintained by the National Library of Medicine. NCT05849103 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.